IO Biotech, Inc. IOBT 深 滬
等待開盤 11-26 09:30:00 美东时间
0.7272
-0.062
-7.84%
華盛通- 最 高0.7879
- 今 開0.765
- 成交量 100.91万股
- 最 低 0.6904
- 昨 收 0.7891
- 總市值 4790.86万
- 52周最高 2.79
- 市盈率 靜 --
- 換手率 1.53%
- 52周最低 0.3234
- 委 比 -30.51%
- 總股本 6588.09万
- 歷史最高 17.88
- 量 比 1.72
- 振 幅 12.36%
- 歷史最低 0.3234
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
IO Biotech Presents at Jefferies Global Healthcare Conference
IO Biotech ( ($IOBT) ) has provided an announcement. IO Biotech, Inc. announced...
11-18 19:58
IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.34) by 61.19 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the
11-14 21:11
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech reported interim results for Phase 3 trial IOB-013 for advanced melanoma, showing clinically relevant progression-free survival (PFS) improvements across subgroups though narrowly missing statistical significance. The company plans to meet with the FDA in December to discuss a potential new Phase 3 registrational trial. IO Biotech also presented pre-clinical data for IO112 and IO170 candidates at the SITC Annual Meeting. The company en...
11-14 13:05
IO Biotech To Present New Pre-Clinical Data For Next Vaccine Candidate, IO112, And Additional Candidate, IO170, At SITC 2025
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted
11-07 22:06
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...
10-27 20:30
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS)
10-20 14:48
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
IO Biotech's Phase 3 trial shows Cylembio plus pembrolizumab achieves 19.4-month median progression-free survival (mPFS) vs 11.0 months with pembrolizumab alone in advanced melanoma, narrowly missing statistical significance. Subgroup analyses show consistent PFS improvements across PD-L1-negative, BRAF V600-mutated, and elevated LDH patients. The combination is well-tolerated, with no added systemic toxicity. Final Phase 2 basket trial data in N...
10-20 06:30
